Search Results

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

First Validation of Novel PRI Technology: Existing PET Tracers Can Image Tissue Microenvironment

August 6, 2026 - A joint research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK announced that they have established a novel geometric imaging principle utilizing positron three-photon decay and successfully validated Positronium Ratio Imaging (PRI) technology for the first time. This method can be used in conjunction with existing clinical PET tracers and is expected to provide a new means of observing tissue microenvironments in nuclear medicine imaging. Conceptual diagram of next-generation nuclear medicine imaging utilizing positron-3-photon decay. Current clinical PET scans primarily rely on the positron two-photon annihilation process to visualize the distribution and accumulation of tracers in the body, but they provide limited information on microenvironmental factors such as tissue hypoxia that are associated with disease malignancy...

2026-08-07

Petrovietnam Calls for Synchronized Regulation and Development in Ninh Thuan 2 Nuclear Power Project

Petrovietnam has proposed adopting a synchronized coordination mechanism in the development of the Ninh Thuan 2 nuclear power project. The Group believes that for this nuclear power plant project, regulatory, licensing, and inspection procedures should proceed in parallel with the project development process during the investment preparation phase. This approach can enhance document quality, control risks, and ensure the project is implemented safely and in compliance with standards. Petrovietnam emphasized that nuclear power projects require regulatory work (including licensing, assessment, and review) to be integrated into all stages of the project lifecycle, rather than being treated as a subsequent step. The Vietnam Oil and Gas Group proposed that, to effectively advance project preparation, regulatory capacity building should be strengthened...

2026-08-06

Japanese PET Study Suggests Late-Onset Psychosis May Be Linked to Neurodegenerative Pathology

A nuclear medicine imaging study conducted by a Japanese research team has shown that many adults who experience psychotic symptoms such as hallucinations and delusions for the first time after age 40 have abnormal protein deposits in the brain associated with Alzheimer's disease and other neurodegenerative disorders. The study included 37 patients with late-onset psychosis and 47 age-matched healthy controls. The researchers used the amyloid PET tracer ^11C-PiB and the tau protein PET tracer ^18F-florzolotau to assess the accumulation of β-amyloid and tau proteins in the participants' brains. The results showed that among patients with late-onset psychosis, β-amyloid positivity...

2026-08-06

CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously

Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.

2026-08-06

US Intermountain Health Opens New Outpatient Clinic in Las Vegas, Equipped with PET/CT and Linear Accelerator

Intermountain Health, headquartered in Salt Lake City, recently opened a new outpatient clinic in southwest Las Vegas. Named Badura Clinic, the facility spans approximately 90,000 square feet and is located in the Spring Valley area, marking the health system's first new construction project in Nevada. The three-story Badura Clinic officially opened following a ribbon-cutting ceremony and community open house on July 30. The clinic consolidates primary care and select specialty services previously dispersed across multiple locations in the Las Vegas Valley, offering more centralized medical care for children, adults, and senior patients. According to the introduction, the clinic's services include adult and...

2026-08-05

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

United Imaging Healthcare's New-Generation Digital PET/CT "uMI Panvivo" Enters Clinical Use in Japan

August 3 news, United Imaging Healthcare Japan Co., Ltd. announced that the first unit in Japan of its new-generation digital PET/CT scanner uMI Panvivo has been put into clinical use at Saitama Central Clinic, located in Omiya-ku, Saitama City. Saitama Central Clinic is a medical institution specializing in diagnostic imaging. Since its opening in 2009, the clinic has continuously conducted comprehensive cancer screening centered on PET/CT scans, and provides FDG-PET cancer examination services based on the needs of local medical institutions, with an annual PET/CT examination volume ranking among the highest in Japan. With the introduction of uMI Panvivo, the clinic expects to further shorten examination time and enhance image quality on the basis of its existing high-precision diagnostic imaging...

2026-08-03

Radiation protection expert Peter Bryant to lead University of Liverpool's Chadwick Institute for Nuclear Innovation

The University of Liverpool has announced that Professor Peter Bryant has been appointed as the Director of the newly established Chadwick Institute for Nuclear Innovation, with his tenure officially commencing in September 2026. The Chadwick Institute for Nuclear Innovation is named after Nobel laureate Sir James Chadwick, who served as Head of the Physics Department at the University of Liverpool and is renowned for his discovery of the neutron. The Institute will leverage the University of Liverpool's research expertise, innovative facilities, and strategic partnerships in the nuclear energy sector to advance research and talent development in nuclear innovation. Bryant has long been engaged in work related to the civil nuclear fuel cycle, with his research and management portfolio encompassing radiation protection, environmental permitting, radioactive waste...

2026-08-03

Yunnan Caiyunhui Innovation Competition Semifinals Conclude, Irradiation Technology Application Projects Debut

On July 29, the semifinals of the 2026 Caiyunhui Innovation Competition Yunnan Division, themed "Caiyunhui, Win the Future," concluded at Kunming City College. The semifinals covered five industry sectors: next-generation information technology, biomedicine, high-end equipment manufacturing, new materials, new energy, and energy conservation and environmental protection, with 301 enterprises from Yunnan Province advancing to the semifinals. In terms of participant composition, 111 enterprises were in next-generation information technology and 104 in biomedicine, with these two categories accounting for over 70% of the total semifinalists, making them the key tracks of this year's Yunnan Division. In the startup group, projects in next-generation information technology and biomedicine rose to 67%, reflecting that local science and technology innovation projects in Yunnan are extending from traditional industry tracks to emerging industry tracks.

2026-08-01

Curium Advances Second Cyclotron Investment Plan in Romania to Expand PET Imaging Supply

On July 30, Curium announced that it is advancing its second cyclotron investment plan in Romania to expand access to advanced nuclear medicine services locally and further strengthen healthcare infrastructure. According to the introduction, after completing assessments of market opportunities, technical requirements, and regional infrastructure, Curium has identified the Cluj-Napoca region as the preferred site for the project and selected a preferred local partner. Preparatory work is currently underway to support the project's progression to the next phase. This expansion plan aims to increase relevant production capacity, enhance PET imaging equipment and service supply capabilities, improve patient access to advanced diagnostic procedures, and support the...

2026-07-30

Shanghai Petrochemical's Black High-Density Polyethylene Special Material Obtains Nuclear Power Application Qualification

On July 28, Shanghai Petrochemical disclosed that its self-developed black high-density polyethylene special material YGH041TLSH has passed the certification of the American Plastics Pipe Institute (PPI). After passing this certification, Shanghai Petrochemical has become the first domestic supplier of high-end polyethylene pipe materials with nuclear power application qualifications, marking a breakthrough in China's long-term reliance on imports for polyethylene pipe raw materials used in nuclear power water supply and drainage systems. Nuclear power pipelines are one of the important supporting systems of nuclear power plants, with significantly higher requirements for material reliability and safety compared to ordinary municipal pipelines. Taking the 813 mm large-diameter pipeline used in the cooling system of a nuclear power plant as an example, its wall thickness is more than twice that of ordinary pipelines, and the design life requirement reaches...

2026-07-29